TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05644691

Intervention type: OTHER
Intervention: Lipikar Baume AP+M
Description: application of Lipikar Baume AP+M twice daily for 3 months in parallel with the corticosteroid treatment

Intervention type: OTHER
Intervention: Usual emollient
Description: application of the usual emollient twice daily for 3 months in parallel with the corticosteroid treatment
Study: NCT00206466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin/cytoxan
Description: Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
Study: NCT01211847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide Choline Controlled-Release Tablet
Description: DCCR 290 mg once a day for 126 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching DCCR
Study: NCT02449603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic insulin Aspart 30
Study: NCT03989115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-4630
Description: RMC-4630 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-4630
Description: RMC-4630 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Osimertinib
Description: Osimertinib for oral administration
Study: NCT03903640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune
Description: -Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: -Standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: -Standard of care
Study: NCT04281056

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth removal and their replacement by means of a denture
Description: Teeth have been removed and replaced by means of dentures for at least one year
Study: NCT04111133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betablocker + ivabradine
Description: Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betablocker
Description: Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.
Study: NCT02141386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)
Study: NCT00226694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
Study: NCT02157233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rest

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Rest
Study: NCT03950765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological momentary intervention
Description: Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
Study: NCT02157233

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Exercise
Study: NCT00320658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP1 42-C1/Alhydrogel
Description: Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP1 42-C1/Alhydrogel
Description: Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP1 42-C1/Alhydrogel
Description: Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP1 42-C1/Alhydrogel
Description: Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPG 7909
Description: Adjuvant
Study: NCT01018901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Patients complete survey
Study: NCT02238977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Antidepressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Antidepressant
Study: NCT04570826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation.
Description: The caregivers received eight sessions lasting each one two hours with the following sequence: before each practical exercises they always received 15 minutes about scientific theoretical evidence explaining the importance of doing them: to get a comfortable posture they received 25 minutes of mobility, flexibility, balance, strength and endurance exercises. To increase lung capacity, 25 minutes of costal, diaphragmatic and clavicular breathing exercises. Finally, to have an open attitude without distractions or judging they practiced 25 minutes of body awareness exercise observing sensations, thoughts and perceptions with gratitude and compassion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scientific descriptions about meditation.
Description: The control group received scientific descriptions about meditation.
Study: NCT03564912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Oral Tablet [Xeloda]
Description: 2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine Oral Tablet [Xeloda]
Description: 2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
Study: NCT04157179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide
Description: Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide
Description: Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide
Description: Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
Study: NCT00601926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg over 90 minutes every 3 weeks
Study: NCT04223011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Hospital Recovery Coach Intervention
Description: The recovery coach will meet with the patient at least once during the hospital admission, during which he/she will reinforce the importance of continuing medication treatments, if initiated, as well as community and social supports for recovery and will discuss the plan for engaging in these services. This will include recommendations for suitable community resources for recovery services, or for housing, transportation, or other external barriers that may make it more difficult to engage in outpatient treatment. The recovery coach will encourage the participant to complete a relapse prevention plan, and help the patient organize post-discharge appointments and review medications. If applicable, family members and significant others will be encouraged to be present for these encounters.
Study: NCT02580097

Intervention type: OTHER
Intervention: MRI
Description: MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.
Study: NCT01845610

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
Description: Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified fat-based paste with essential fatty acids
Description: Complementary food supplement fortified with micronutrients and essential fatty acids
Study: NCT02532660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Description: Escitalopram 10mg (1 pill once a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram 10mg
Description: Escitalopram 10mg (1 pill once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABCAT TCJUSS
Description: LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABCAT TCJUSS
Description: LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LABCAT TCJUSS Placebo
Description: LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Placebo
Description: Escitalopram Placebo (1 pill once a day)
Study: NCT00126516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II Receptor Antagonists
Description: any dosage, frequency, and duration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin-converting Enzyme Inhibitors
Description: any dosage, frequency, and duration
Study: NCT03447782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl (Bulk) Powder
Description: For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder
Study: NCT04300738

Intervention type: DEVICE
Group type: OTHER
Intervention: CCS wit CT Scann measurement
Description: Measurement with 2 devices
Study: NCT00550225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
Study: NCT02002247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium selenite
Description: All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
Study: NCT00550225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 matching placebo
Description: GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 matching placebo
Description: GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
Study: NCT03121846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
Study: NCT01982513

Intervention type: DEVICE
Intervention: Ultrasound
Description: The IVC will be visualized and images obtained using the intercostal window in both longitudinal and transverse planes.
Study: NCT00382200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tretinoin

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study: NCT03285828

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: motivationnal interviewing training
Description: The students received three four-hour sessions of basic motivationnal interviewing training :~1. Viewing and commenting on video clips illustrating motivational and non-motivational doctor-patient interactions.~2. Lectures and the distribution of memory aids.~3. Practical exercises: making reflections, asking open questions; exploring ambivalence; dealing with resistance; expressing empathy, summarising.~4. Role-playing, based on several situations, each involving two students. The investigators deliberately chose a non-medical situation (conflict between a mother and a student asking her for pocket money to go out for fun, the day before a university examination) for the first situation. All the other situations concerned changes to healthier behaviour in a medical setting, but with a goal different from that used for the first or the second simulated interview before motivationnal interviewing training.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: motivationnal interviewing training
Description: The students received three four-hour sessions of basic motivationnal interviewing training :~1. Viewing and commenting on video clips illustrating motivational and non-motivational doctor-patient interactions.~2. Lectures and the distribution of memory aids.~3. Practical exercises: making reflections, asking open questions; exploring ambivalence; dealing with resistance; expressing empathy, summarising.~4. Role-playing, based on several situations, each involving two students. The investigators deliberately chose a non-medical situation (conflict between a mother and a student asking her for pocket money to go out for fun, the day before a university examination) for the first situation. All the other situations concerned changes to healthier behaviour in a medical setting, but with a goal different from that used for the first or the second simulated interview before motivationnal interviewing training.
Study: NCT02760537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lay Health Worker Intervention
Description: Lay Health Worker Phone Intervention The second phase addressed phone intervention training, where LHWs who had completed the first phase and were willing to participate in the second phase learned the process for calling participants to remind them to complete a series of HBV vaccinations. The LHWs assigned to the intervention group conducted phone interventions by reminding participants about completing a series of vaccinations at Months 1, 2, and 6, and also provided accompanying resources and support.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (a list of resources)
Description: Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
Study: NCT02931344

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Dietary Supplement: Intensive dietary intervention
Description: Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
Study: NCT00954811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300IU rec-LH
Description: luteal alternate doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone 600mg
Description: luteal support
Study: NCT02204072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Study: NCT02543294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiograms
Description: Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiograms
Description: Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiograms
Description: Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Electrocardiogram performed at baseline.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Electrocardiogram performed at baseline.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Electrocardiogram performed at baseline.
Study: NCT02002247

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.